Sera Prognostics (SERA)
(Delayed Data from NSDQ)
$10.85 USD
+0.22 (2.07%)
Updated May 3, 2024 04:00 PM ET
After-Market: $10.81 -0.04 (-0.37%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.85 USD
+0.22 (2.07%)
Updated May 3, 2024 04:00 PM ET
After-Market: $10.81 -0.04 (-0.37%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Zacks News
Sera Prognostics (SERA) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Sera Prognostics (SERA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sera Prognostics (SERA) delivered earnings and revenue surprises of 0% and 56.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Sera Prognostics, Inc. (SERA) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Sera Prognostics, Inc. (SERA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why You Should Bet on These 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Yum Brands (YUM), Inter Parfums (IPAR), TripAdvisor (TRIP) and Sera Prognostics (SERA).
Why You Should Bet on 4 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Scholar Rock (SRRK), PTK Acquisition (VLN), OI Glass (OI) and Sera Prognostics (SERA).
Sera Prognostics, Inc. (SERA) Loses -32.38% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Sera Prognostics, Inc. (SERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Sera Prognostics, Inc. (SERA) Loses -38.49% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Sera Prognostics, Inc. (SERA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 0% and 29.47%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Sera Prognostics, Inc. (SERA) Reports Q1 Loss
by Zacks Equity Research
Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 2.86% and 0%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Alignment Healthcare (ALHC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 20% and 1.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Eli Lilly (LLY) Q1 Earnings Lag Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of -6.36% and 2.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Sera Prognostics, Inc. (SERA) Loses -13.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Sera Prognostics, Inc. (SERA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
UnitedHealth (UNH) Arm to Reduce Prior Authorization Time
by Zacks Equity Research
UnitedHealth's (UNH) UnitedHealthcare business to lower the use of prior authorization process or preauthorization by almost 20%.
Tenet Healthcare (THC) Jumps 14.9% YTD: More Growth Ahead?
by Zacks Equity Research
Tenet Healthcare's (THC) focus on boosting USPI's network is positioning the company for expedited growth.
Elevance (ELV) Arm to Bring Virtual-First Plans to Georgia
by Zacks Equity Research
The cocktail of virtual and in-person options from Elevance Health's (ELV) part of the Anthem family of brands is expected to enrich members' health experience.
All You Need to Know About Sera Prognostics, Inc. (SERA) Rating Upgrade to Buy
by Zacks Equity Research
Sera Prognostics, Inc. (SERA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 26.19% and 50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 8.82% and 1.92%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 12.50% and 2.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of -55.10% and 1.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 7.50% and 22%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cano Health, Inc. (CANO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cano Health, Inc. (CANO) delivered earnings and revenue surprises of 25% and 2.98%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
GoodRx Holdings, Inc. (GDRX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 50% and 4.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sera Prognostics, Inc. (SERA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Sera Prognostics, Inc. (SERA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.